Initial antimicrobial treatment of foals with sepsis: Do our choices make a difference?

被引:18
|
作者
Theelen, Mathijs J. P. [1 ,2 ]
Wilson, W. David [3 ]
Byrne, Barbara A. [4 ]
Edman, Judy M. [3 ]
Kass, Philip H. [5 ]
Magdesian, K. Gary [3 ]
机构
[1] Univ Utrecht, Fac Vet Med, Dept Equine Sci, Yalelaan 112, NL-3584 CM Utrecht, Netherlands
[2] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands
[3] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, 1 Shields Ave, Davis, CA 95616 USA
[4] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, 1 Shields Ave, Davis, CA 95616 USA
[5] Univ Calif Davis, Sch Vet Med, Dept Populat Hlth & Reprod, 1089 Vet Med Dr, Davis, CA 95616 USA
来源
VETERINARY JOURNAL | 2019年 / 243卷
关键词
Amikacin; Ampicillin; Antimicrobial resistance; Equine; Neonatal intensive care unit; SUSCEPTIBILITY PATTERNS; SURVIVAL; BLOOD; BACTEREMIA;
D O I
10.1016/j.tvjl.2018.11.012
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The study objectives were to provide cumulative antimicrobial susceptibility data at the patient level and to evaluate the effect of initial antimicrobial treatment on survival in foals with sepsis. Foals below 30 days of age with a diagnosis of sepsis, confirmed by isolation of bacteria from normally sterile sites on the day of hospital admission, were included. Susceptibility testing was performed using the broth microdilution procedure. In total, 213 foals and 306 bacterial isolates were included. The likelihood of survival for foals from which all bacteria were susceptible to the initial antimicrobial treatment was 65.4% (n = 106/162; 95% confidence interval (CI) 57.6% to 72.7%) versus 41.7% (n =10/24; 95% CI 22.1% to 63.4%) if one or more isolates were resistant (relative risk 1.57, 95% CI 0.96 to 3.06). Based on this study, amikacin combined with ampicillin remains an appropriate antimicrobial drug combination for initial treatment of foals with sepsis. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:74 / 76
页数:3
相关论文
共 48 条
  • [31] OUTCOMES OF VETERAN'S ADMINISTRATION PROSTATE CANCER PATIENTS: DO TREATMENT PATTERNS AND ACCESS TO CARE MAKE A DIFFERENCE?
    Sackman, Daniel
    Acevedo, Ann Martinez
    Park, Byung
    Amling, Christopher
    JOURNAL OF UROLOGY, 2016, 195 (04): : E856 - E856
  • [32] Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?
    Landi, Lorenza
    Cappuzzo, Federico
    JOURNAL OF THORACIC DISEASE, 2012, 4 (02) : 226 - 228
  • [33] How much do rheumatologists make a difference?: Two strategies to improve treatment of osteoporosis following fragility hip fracture
    Boire, G
    Cabana, F
    De Brum-Fernandes, AJ
    Liang, P
    Robindaine, J
    Hercelin, D
    Deschênes, I
    Roux, S
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 348 - +
  • [34] The Impact of Drug Treatment on Recidivism: Do Mandatory Programs Make a Difference? Evidence From Kansas's Senate Bill 123
    Rengifo, Andres F.
    Stemen, Don
    CRIME & DELINQUENCY, 2013, 59 (06) : 930 - 950
  • [35] How do renal clinicians present treatment options to older patients with advanced kidney disease and what difference does it make?
    Selman, Lucy E.
    Shaw, Chloe
    Sowden, Ryann
    Murtagh, Fliss
    Caskey, Fergus
    Tulsky, James
    Parry, Ruth
    Barnes, Rebecca
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1173 - I1175
  • [36] How do renal clinicians present treatment options to older patients with advanced kidney disease and what difference does it make?
    Selman, Lucy E.
    Shaw, Chloe
    Sowden, Ryann
    Murtagh, Fliss
    Caskey, Fergus
    Tulsky, James
    Parry, Ruth
    Barnes, Rebecca
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [37] Do psychiatrists make a difference? Impact of levels of medical input to the range of treatment provided in in-patient drug detoxification services
    Day, Ed
    Best, David
    Ison, Julie
    Keaney, Francis
    Strang, John
    Buntwal, Neena
    DRUGS-EDUCATION PREVENTION AND POLICY, 2006, 13 (06) : 577 - 585
  • [38] Does timing of initial surfactant treatment make a difference in rates of chronic lung disease or mortality in premature infants? An observational regional study
    Premnath, Daphne
    Kent, Alison Louise
    Bajuk, Barbara
    Abdel-Latif, Mohamed E.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2016, 29 (01): : 91 - 98
  • [39] Overview, definitions, and goals for ASHA's treatment outcomes and clinical trials activities (what difference do outcome data make to you?)
    Baum, HM
    LANGUAGE SPEECH AND HEARING SERVICES IN SCHOOLS, 1998, 29 (04) : 246 - 249
  • [40] Treatment choices for elderly-onset rheumatoid arthritis (EORA) do not reflect any clinical difference from younger-onset rheumatoid arthritis (YORA).
    Harrison, MJ
    Kim, CA
    Lachs, MH
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S539 - S539